Jinzhong

Major Depressive Disorder MDD is a chronic condition causing significant illness and disability, especially among children and adolescents worldwide. This trial studies the use of bright light therapy BLT in adolescents aged 13 to 17 with MDD, aiming to evaluate its effectiveness, speed of improvement, safety, and how it may improve emotional and cognitive functions. The research also explores the brain mechanisms involved in these effects using imaging techniques. Participants with MDD will be randomly assigned to one of three groups high-intensity bright white light therapy 10,000 lux, medium-intensity bright white light therapy 5,000 lux, or a placebo group receiving dim red light 100 lux. Each participant will undergo 40 minutes of light exposure between 630 and 1000 AM, six days a week, for four consecutive weeks. Healthy adolescent controls will also be included for comparison and brain imaging studies. During the study, participants will be assessed weekly during the light therapy period and followed for two weeks afterward. Assessments include depression severity using the Hamilton Depression Rating Scale, anxiety, sleep quality, cognitive function, irritability, self-injury behaviors, and safety monitoring. Advanced brain imaging using functional Near-Infrared Spectroscopy fNIRS and MRI will be conducted to investigate the neural effects of light therapy. This study aims to provide comprehensive data on the benefits and mechanisms of BLT in adolescent depression.

Researchers are investigating the effects of bright light therapy BLT on cognitive impairment in adults with major depressive disorder MDD. This study aims to validate the safety and effectiveness of BLT for improving cognitive function, understand brain circuit changes related to treatment, and explore how these brain changes influence cognitive outcomes. Participants must be adults with MDD, either on stable selective serotonin reuptake inhibitor SSRI monotherapy for at least four weeks or medication-free before joining. Participants will be randomly assigned to one of two groups the experimental group receiving bright light therapy at 10,000 lux, or the control group receiving dim red light at less than 100 lux. Both groups will undergo their respective light interventions for 40 minutes per day, six days a week, between 7 AM and 10 AM, for four weeks. The study includes a follow-up visit four weeks after the intervention ends. During the study, participants will keep a daily record of light exposure and complete a sleep diary. Throughout the study, various assessments will be conducted to evaluate cognitive function, depression, anxiety, sleep quality, quality of life, and side effects. These include standardized cognitive tests, depression and anxiety rating scales, sleep and quality of life questionnaires, and safety evaluations. Functional and structural MRI scans will be performed before and after the intervention to observe brain changes. Evaluations occur at baseline and multiple time points during and after treatment, with ongoing monitoring of symptoms and treatment adherence.

This research aims to study patients with unresectable non-small cell lung cancer NSCLC who receive nintedanib alongside sequential radiotherapy. The study evaluates the occurrence of significant radiation pneumonitis above grade 2 and monitors the safety of combining nintedanib with radiotherapy. Additionally, the study will observe progression-free survival PFS and overall survival OS in patients treated with nintedanib plus radiotherapy and immunotherapy. Participants will first undergo induction therapy, including chemotherapy andor immunotherapy for at least one cycle. Following this, they will receive sequential radiotherapy combined with nintedanib treatment for six months. After completing this phase, patients will continue with maintenance immunotherapy for 16 cycles as part of their treatment plan. Throughout the study, participants will be monitored for safety and the incidence of radiation pneumonia for up to two years. Lung function, PFS, and OS will also be assessed during this period. The total follow-up and observation will last up to two years to evaluate these outcomes and monitor patient health comprehensively.

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.

Researchers are studying cardiovascular diseases CVD including coronary heart disease, atrial fibrillation, and chronic heart failure in participants aged 40 years or older. The study aims to describe how common chronic obstructive pulmonary disease COPD is among these participants and to observe how combined heart and lung care affects their short-term health outcomes. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease group. The study uses a behavioral intervention that includes guideline education and implementation at both the investigator and patient levels. Investigators receive disease education before enrollment, and cardiologists and pulmonologists provide ongoing disease education and coordinated treatment every four weeks. Participants will be followed up every four weeks to manage their care and monitor progress. Participants will undergo spirometry testing and complete questionnaires to assess their lung and heart health. Researchers will measure COPD prevalence, hospitalization rates, symptom scores, lung function, and other heart and lung-related biomarkers over 12 weeks. The study includes assessments of treatment adherence and changes in health status through repeated evaluations at baseline and weeks 4, 8, and 12. Safety and outcomes will be closely monitored throughout the study period.

Researchers are evaluating the preliminary effectiveness and safety of Tislelizumab combined with thoracic radiotherapy and chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer. This is a phase II, single-arm, open, multicenter study aiming to explore this combination therapy in people newly diagnosed with this condition. Participants will receive Tislelizumab infusions 200 mg every 3 weeks for up to 2 years. They will also receive chemotherapy with Etoposide plus either Carboplatin or Cisplatin for 4 cycles every 3 weeks. Concurrent thoracic radiotherapy will be given using intensity-modulated radiation therapy IMRT with doses between 30 to 45 Gy over 10 to 15 fractions. Throughout the study, participants will be closely monitored with imaging to assess tumor response and disease progression for up to 2 years. Researchers will track progression-free survival as the main outcome, along with response rates, overall survival, and any side effects. Participants will have regular visits for assessments and follow-ups to monitor treatment effects and safety during and after therapy.